Merck (MRK) is pushing into one of the pharmaceutical industry’s most closely watched therapeutic categories with its newly developed oral cholesterol treatment, Lipfendra. The drug belongs to the PCSK9 inhibitor class, a
More
Women’s health is no longer a narrow policy category on the margins of federal attention, and the consequences for the FemTech industry are significant. FemTech now spans menstrual health, fertility, pregnancy and
More
Philadelphia’s Fair Criminal Record Screening Standards Ordinance has been significantly updated, and employers across the city must now navigate a more detailed set of requirements. The Philadelphia Commission on Human Relations issued
More
LinkedIn has long been dismissed as a passive résumé platform, but legal business development coach Steve Fretzin argues it is far more powerful than that. Fretzin, a five-time bestselling author and host
More
Jackson Walker, the Texas-based law firm, has agreed to pay $15 million to resolve a federal lawsuit stemming from a romantic scandal involving a sitting bankruptcy judge. The U.S. Trustee, the Justice
More
St. James’s Place (LSE: STJ) has attracted one of the most bullish price targets on the FTSE 100, with Deutsche Bank forecasting the wealth manager’s shares could surge close to 100%. From
More
Global equity markets are showing renewed momentum in 2026, with analysts pointing to a combination of easing inflation pressures and resilient corporate earnings as key drivers. Investors have grown increasingly optimistic that
More
The FTSE 250 index continues to attract attention from analysts and retail investors seeking undervalued opportunities in the current UK market environment. Mid-cap stocks listed on the FTSE 250 have historically offered
More
With Glorious Goodwood now behind us, the York Ebor Festival takes centre stage as the next major fixture on the racing calendar. Several races from the Knavesmire are already available to bet
More
Amgen is pushing deeper into cardiovascular medicine as its cholesterol drug Repatha continues to gain ground following a significant regulatory milestone. The US Food and Drug Administration granted Repatha a label expansion
More